Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1 h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer

A compound of Formula (I)

• or a tautomer or a stereoisomeric form thereof, wherein
• X1 represents
• wherein
• R1, R1a, R1b, R1c, and R2 each independently represent hydrogen;
• or C1-6alkyl optionally substituted with one or two substituents each independently selected from the group consisting of Het1, —OR3, and —NR4aR4b;
• Het1 represents morpholinyl or tetrahydropyranyl;
• R3 represents hydrogen, C1-4alkyl, —C2-4alkyl-O—C1-4alkyl, —C2-4alkyl-OH, or —C2-4alkyl-O—C2-4alkyl-O—C1-4alkyl;
• R4a and R4b are each independently selected from the group consisting of hydrogen and C1-4alkyl;
• X2 represents
• which can be attached to the remainder of the molecule in both directions;
• Y1 represents —O—, —S—, —S(═O)—, —S(═O)2—, or —N(Rx)—;
• Rx represents hydrogen, methyl, C2-6alkyl, —C(═O)—C1-6alkyl, —S(═O)2—C1-6alkyl, C3-6cycloalkyl, —C(═O)—C3-6cycloalkyl, or —S(═O)2—C3-6cycloalkyl;
• wherein C2-6alkyl, —C(═O)—C1-6alkyl, —S(═O)2—C1-6alkyl, C3-6cycloalkyl, —C(═O)—C3-6cycloalkyl, and —S(═O)2—C3-6cycloalkyl are optionally substituted with one, two or three substituents selected from the group consisting of halo, C1-4alkyl and C1-4alkyl substituted with one, two or three halo atoms;
• Y2 represents —CH2—, —S— or —S(═O)2—;
• Ry represents halo;
• n represents 0, 1 or 2;
• m represents 0 or 1;
• or a pharmaceutically acceptable salt, or a solvate thereof.